It decreased glycated hemoglobin (HbA1c) by 0.78% at maximum dosages [88]
Commercial launch prices: projected $1,000$1,500/month before discounts Compounded versions: $200$600/month, varies by dose and supplier Starting or sub-clinical doses are less than $100 per month, sometimes below $50
Not provided for clinical use, human consumption, or veterinary application outside of laboratory research settings
Most participants (39.1%) had been using GLP-1RA for over a year
However, the decision about whether to wean off or stop suddenly should be individualised and made in consultation with your prescribing clinician
The retatrutide dosing guidance does not specify food requirements, but personal experimentation is valuable